Led by serial biotech entrepreneur Greg Verdine, the startup mined fungi genomes to find a safer alternative to the drugs widely used to prevent the body from rejecting transplanted organs.

Led by serial biotech entrepreneur Greg Verdine, the startup mined fungi genomes to find a safer alternative to the drugs widely used to prevent the body from rejecting…

LifeMine Therapeutics raises $263M across Series D and E rounds to advance LIFE-001, a fungal-derived calcineurin inhibitor for transplant patients.